Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals
Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, Geleijnse JM, Rauch B, Ness A, Galan P, Chew EY, Bosch J, Collins R, Lewington S, Armitage J, Clarke R, Omega-3 Treatment Trialists’ Collaboration
JAMA cardiology · 462 citations
How it was studied
- Design
- Meta-analysis (indexed by PubMed)
- Studied in
- People
- Main outcome
- Clinical events such as disease or death
Who paid for it
- Funding
- Independent funding
- Government
- National Institute for Health and Care Research
- Nonprofit
- British Heart Foundation
- Government
- National Institute for Health Research (NIHR)
- Grants
- National Institute for Health and Care Research (NF-SI-0513-10083); British Heart Foundation (PG/12/32/29544)
Based on 3 listed funder(s).
Publication
- Published
- 2018-01-31 · JAMA Cardiol · vol. 3 · issue 3 · p. 225
- Publisher
- American Medical Association
- Cited
- 641 citations · more than 100% of similar papers · 60.8× the field average
- Impact
- Top 10% most cited in its field
- References
- 35 works
- Access
- Open access (hybrid journal) · CC-BY
- Research areas
- Fatty Acid Research and Health · Vitamin K Research Studies · Nutrition, Genetics, and Disease
- Keywords
- Medicine, Myocardial infarction, Internal medicine, Population, Confidence interval, Randomized controlled trial, Stroke (engine), Cardiology, Relative risk, Clinical trial, Hazard ratio, Environmental health
- MeSH
- humans, cardiovascular diseases, coronary disease, myocardial infarction, fatty acids, omega-3, cause of death, risk factors, dietary supplements, middle aged, female, male, randomized controlled trials as topic, stroke
16 authors
From GB, NL, CA, IT, DE, FR, US
- Theingi AungRoyal Berkshire Hospital; University of Oxford; Medical Research Council
- Jim HalseyUniversity of Oxford; Medical Research Council
- Daan KromhoutUniversity of Groningen
- Hertzel C. GersteinPopulation Health Research Institute; Hamilton Health Sciences; McMaster University
- Roberto MarchioliMario Negri Institute for Pharmacological Research; Istituti di Ricovero e Cura a Carattere Scientifico
- Luigi TavazziMaria Cecilia Hospital
Abstract
Importance
Current guidelines advocate the use of marine-derived omega-3 fatty acids supplements for the prevention of coronary heart disease and major vascular events in people with prior coronary heart disease, but large trials of omega-3 fatty acids have produced conflicting results.
Objective
To conduct a meta-analysis of all large trials assessing the associations of omega-3 fatty acid supplements with the risk of fatal and nonfatal coronary heart disease and major vascular events in the full study population and prespecified subgroups.
Data sources and study selection
This meta-analysis included randomized trials that involved at least 500 participants and a treatment duration of at least 1 year and that assessed associations of omega-3 fatty acids with the risk of vascular events.
Data extraction and synthesis
Aggregated study-level data were obtained from 10 large randomized clinical trials. Rate ratios for each trial were synthesized using observed minus expected statistics and variances. Summary rate ratios were estimated by a fixed-effects meta-analysis using 95% confidence intervals for major diseases and 99% confidence intervals for all subgroups.
Main outcomes and measures
The main outcomes included fatal coronary heart disease, nonfatal myocardial infarction, stroke, major vascular events, and all-cause mortality, as well as major vascular events in study population subgroups.
Results
Of the 77 917 high-risk individuals participating in the 10 trials, 47 803 (61.4%) were men, and the mean age at entry was 64.0 years; the trials lasted a mean of 4.4 years. The associations of treatment with outcomes were assessed on 6273 coronary heart disease events (2695 coronary heart disease deaths and 2276 nonfatal myocardial infarctions) and 12 001 major vascular events. Randomization to omega-3 fatty acid supplementation (eicosapentaenoic acid dose range, 226-1800 mg/d) had no significant associations with coronary heart disease death (rate ratio [RR], 0.93; 99% CI, 0.83-1.03; P = .05), nonfatal myocardial infarction (RR, 0.97; 99% CI, 0.87-1.08; P = .43) or any coronary heart disease events (RR, 0.96; 95% CI, 0.90-1.01; P = .12). Neither did randomization to omega-3 fatty acid supplementation have any significant associations with major vascular events (RR, 0.97; 95% CI, 0.93-1.01; P = .10), overall or in any subgroups, including subgroups composed of persons with prior coronary heart disease, diabetes, lipid levels greater than a given cutoff level, or statin use.
Conclusions and relevance
This meta-analysis demonstrated that omega-3 fatty acids had no significant association with fatal or nonfatal coronary heart disease or any major vascular events. It provides no support for current recommendations for the use of such supplements in people with a history of coronary heart disease.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.